Zetia Cost in California 2026: Price, Insurance, Medicaid, and Compounding Guide

What Does Zetia Actually Cost in California in 2026?

Generic ezetimibe 10 mg costs roughly $15 per month cash-pay at California retail pharmacies in 2026, while the brand-name Zetia carries a manufacturer list price near $380 per month. The gap between those two numbers is large enough that most California patients who need ezetimibe should never pay the brand price. GoodRx, Costco, and Mark Cuban's Cost Plus Drugs all list generic ezetimibe well below $20 for a 30-day supply at dozens of California ZIP codes.

Brand Zetia is manufactured by Organon (formerly a Merck product) and retains patent-independent pricing because ezetimibe's mechanism, inhibiting the NPC1L1 sterol transporter in the intestinal brush border, is not covered by any active composition-of-matter patent. Generic manufacturers have been free to produce it since 2017, which is why the cash-pay market has collapsed to near-commodity pricing. The FDA's Orange Book lists multiple approved generic ezetimibe 10 mg tablet manufacturers, confirming therapeutic equivalence with brand Zetia. [1]

Ezetimibe lowers LDL-C by roughly 18 to 20 percent as monotherapy, and by an additional 21 to 27 percent when added to a statin, according to data from the SHARP trial (N=9,270) published in The Lancet. [2] That LDL-lowering magnitude is clinically meaningful for patients who cannot tolerate higher statin doses or who have residual LDL elevation despite maximum statin therapy. The American College of Cardiology/American Heart Association 2022 cholesterol guideline identifies ezetimibe as a first non-statin add-on option for patients with ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. [3]

How Generic Pricing Works Versus Brand Zetia

The pharmacy acquisition cost for generic ezetimibe 10 mg in California in 2026 sits between $3 and $8 for a 30-tablet supply at wholesale. Retail markup and dispensing fees bring most cash prices to $10 to $20. Three specific channels consistently beat standard retail pricing for California residents.

Cost Plus Drugs (costplusdrugs.com): Mark Cuban's platform lists generic ezetimibe at approximately $7 for 30 tablets plus a dispensing fee, with mail delivery to California addresses.

GoodRx coupons at California chains: Applying a GoodRx coupon at CVS, Walgreens, Rite Aid, or Walmart in California typically brings the 30-day price to $12 to $18. Prices vary by ZIP code; urban San Francisco and Los Angeles pharmacies may differ from rural Central Valley pricing by a few dollars.

Costco Pharmacy: Costco's internal pricing for generic ezetimibe in California has historically been among the lowest for members, often $10 to $14 for 90 tablets.

The FDA's drug shortage and pricing database confirms no active shortage for ezetimibe 10 mg tablets as of the 2025 reporting period, meaning supply is stable. [4] Patients should compare prices at the specific pharmacy because California's large geographic spread creates real price dispersion even within the same chain.

Does Medi-Cal Cover Ezetimibe in California?

Medi-Cal, California's Medicaid program, covers ezetimibe with prior authorization for most beneficiaries. The preferred drug list managed by the California Department of Health Care Services (DHCS) places generic ezetimibe on its formulary as a non-preferred lipid-lowering agent requiring PA, while high-intensity statins remain preferred first-line agents. [5]

Prior authorization for ezetimibe under Medi-Cal typically requires documentation of one of the following: statin intolerance, failure to achieve LDL-C goal on maximally tolerated statin therapy, or a diagnosis of familial hypercholesterolemia. The PA process can be initiated by the prescribing clinician electronically through the Medi-Cal Rx portal. Approvals for documented statin-intolerant patients are generally granted within 24 to 72 hours according to DHCS processing timelines.

For Medi-Cal managed care plan enrollees (the majority of California Medicaid beneficiaries), the individual plan formulary may differ slightly from fee-for-service Medi-Cal. Plans such as L.A. Care, Health Net, Molina, and Blue Shield Promise each publish their own formulary tiers. Patients should request a formulary exception or PA through their plan's pharmacy benefit manager if ezetimibe is not listed as covered.

The National Lipid Association's 2023 consensus statement on statin intolerance recommends ezetimibe as a primary alternative for patients who cannot tolerate any statin dose: "Ezetimibe should be considered the first non-statin agent in statin-intolerant patients given its safety profile and evidence of cardiovascular benefit." [6]

IMPROVE-IT Trial: Why Clinicians Prescribe Ezetimibe at All

The evidence base for ezetimibe's cardiovascular benefit rests primarily on the IMPROVE-IT trial, published in the New England Journal of Medicine in 2015. IMPROVE-IT enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. At a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm (P<0.001). The primary composite cardiovascular endpoint occurred in 32.7% of the ezetimibe group versus 34.7% of the placebo group (HR 0.936 to 95% CI 0.887 to 0.988, P=0.016). [7]

That 2-percentage-point absolute risk reduction translates to a number-needed-to-treat of 50 over 6 years, which is meaningful at population scale. IMPROVE-IT also confirmed the "lower is better" hypothesis for LDL-C: each 1 mmol/L reduction in LDL-C produced approximately a 20 to 25 percent relative risk reduction in major vascular events, consistent with statin meta-analysis data from the Cholesterol Treatment Trialists' Collaboration published in The Lancet. [8]

For California clinicians managing post-ACS patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin, IMPROVE-IT provides direct support for adding ezetimibe 10 mg daily. The ACC/AHA 2022 guideline incorporates this evidence as a Class I, Level of Evidence A recommendation for secondary prevention in very-high-risk patients. [3]

Which Commercial Insurance Plans Cover Zetia in California?

Most commercial insurance plans operating in California cover generic ezetimibe, though the tier placement and cost-sharing vary considerably. Here is what patients typically encounter.

Covered California plans (ACA marketplace): Bronze, Silver, Gold, and Platinum plans from Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, and Health Net all include generic ezetimibe on formulary, generally at Tier 2 (preferred generic) with copays ranging from $5 to $20 per month after deductible. Brand Zetia, if listed at all, typically appears at Tier 3 or Tier 4 with $50 to $150 copays.

Employer-sponsored plans: Large California employers using PBMs like CVS Caremark, Express Scripts, or OptumRx typically place generic ezetimibe at Tier 1 or Tier 2. Employees with a $0 generic tier pay nothing out-of-pocket for ezetimibe.

Medicare Part D in California: Part D plans are required to cover at least two drugs in every therapeutic class. Generic ezetimibe appears on the formulary of the vast majority of Part D plans available in California. The 2026 Part D redesign, implemented under the Inflation Reduction Act, caps out-of-pocket drug spending at $2,000 per year for Medicare beneficiaries, which further reduces effective ezetimibe costs for older Californians. [9]

If a plan does not cover ezetimibe or places it at an unaffordable tier, clinicians can request a formulary exception by submitting documentation of medical necessity. The AHA/ACC guidelines [3] provide sufficient clinical rationale for most exception requests to succeed.

Is Compounded Ezetimibe Legal in California?

Compounded ezetimibe is legal in California when prepared by a licensed 503A compounding pharmacy operating under California State Board of Pharmacy oversight. A 503A pharmacy compounds on a patient-specific, prescription-by-prescription basis and does not require FDA approval for individual compounds, provided the active pharmaceutical ingredient is used in an FDA-approved drug (which ezetimibe is) and the compounding is not for office stock or resale. [10]

California Board of Pharmacy regulations align with federal 503A requirements under the Drug Quality and Security Act (DQSA) of 2013. Patients in California can legally receive compounded ezetimibe preparations, including ezetimibe in combination with other lipid-lowering agents (such as ezetimibe combined with a statin into a single capsule), when prescribed by a licensed California clinician and prepared by a Board-registered 503A pharmacy.

Cost for compounded ezetimibe at California 503A pharmacies typically ranges from $0 (if covered under a compounding benefit within certain insurance plans) to $30 per month for private-pay patients. Some telehealth platforms include compounded ezetimibe combinations as part of a subscription or medication bundle, bringing the effective monthly cost to near zero when bundled with a cardiovascular management program.

503B outsourcing facilities, which compound larger batches without patient-specific prescriptions, are not permitted to compound ezetimibe under current FDA policy because FDA-approved commercial alternatives exist and ezetimibe is not on FDA's 503B list of bulk drug substances. Prescribers and pharmacies should confirm 503A status before ordering compounded ezetimibe to remain compliant. [10]

Can a California Telehealth Provider Prescribe Ezetimibe?

Yes. Ezetimibe is not a controlled substance and carries no DEA scheduling restrictions, so California-licensed clinicians can prescribe it via synchronous or asynchronous telehealth without limitation. California's telehealth laws, codified under Business and Professions Code Section 2290.5, permit prescribing based on a documented patient evaluation conducted through video, telephone, or store-and-forward technology, as long as the standard of care is met. [11]

Telehealth platforms operating in California, including HealthRX, typically require a lipid panel result before initiating ezetimibe therapy. A baseline LDL-C, total cholesterol, HDL-C, and triglycerides from within the prior 12 months is sufficient for most clinical decision frameworks. Repeat lipid panel at 4 to 12 weeks after starting ezetimibe allows assessment of LDL-C response before titration or adjunctive therapy decisions are made, consistent with the ACC/AHA 2022 guideline recommendation. [3]

Liver function testing is not required before initiating ezetimibe because the drug's hepatic metabolism via glucuronidation does not produce the transaminase elevations seen with statins. The FDA-approved labeling for ezetimibe states that liver function tests are not necessary routinely during treatment. [1]

The HealthRX California Ezetimibe Prescribing Decision Framework

The following tiered approach applies to California patients seeking ezetimibe in 2026, based on payer status and clinical indication.

Step 1. Confirm indication. Ezetimibe is indicated for primary hypercholesterolemia (as monotherapy or adjunct to statin), homozygous familial hypercholesterolemia (adjunct to statin), and sitosterolemia. Confirm LDL-C goal based on ASCVD risk category using the ACC/AHA Pooled Cohort Equations or equivalent tool.

Step 2. Check formulary before prescribing brand. Generic ezetimibe 10 mg is therapeutically equivalent to brand Zetia per the FDA Orange Book. Write the prescription as "ezetimibe 10 mg" and allow generic substitution. This single step drops the cost from ~$380 to ~$15 for cash-pay patients.

Step 3. Apply a discount card if no insurance. GoodRx, RxSaver, and Cost Plus Drugs consistently price generic ezetimibe below $20 in California. The Organon patient assistance program (Merck Helps, now administered by Organon) may provide brand Zetia at no cost for uninsured patients below 600 percent of the federal poverty level.

Step 4. Submit PA for Medi-Cal. Document LDL-C value, current statin therapy and dose, and clinical rationale (statin intolerance or residual LDL elevation). Most PAs are approved within 1 to 3 business days.

Step 5. Consider compounded combination for adherence. For patients on both ezetimibe and a statin who report pill-burden-related non-adherence, a California 503A pharmacy can compound a combination capsule. Non-adherence to lipid-lowering therapy remains a major barrier to outcomes, with one analysis in JAMA Internal Medicine finding that only 50 percent of patients remain adherent to statin therapy at 1 year. [12]

Ezetimibe Safety and Monitoring in California Practice

Ezetimibe 10 mg once daily is generally well tolerated. The most commonly reported adverse effects in clinical trials were upper respiratory infection (4.3%), diarrhea (4.1%), and arthralgia (3.0%), all similar to placebo rates in IMPROVE-IT. [7] Myopathy has been reported rarely when ezetimibe is combined with statins, but the rate is not higher than statin monotherapy according to the SHARP trial data. [2]

Drug interactions are limited but clinically relevant in California practice. Cyclosporine substantially increases ezetimibe plasma concentrations; dose adjustment or monitoring is needed in transplant patients on calcineurin inhibitors. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption and should be administered at least 2 hours before or 4 hours after ezetimibe. The FDA label confirms these interactions explicitly. [1]

Pregnancy and lactation: Ezetimibe is FDA Pregnancy Category X (now described under the PLLR framework as contraindicated in pregnancy) because cholesterol biosynthesis is essential for fetal development. California clinicians should confirm negative pregnancy status and counsel on contraception for women of reproductive age before initiating therapy. The FDA label provides the current reproductive risk summary. [1]

Ezetimibe is not dialyzable and does not require dose adjustment for renal impairment. Moderate or severe hepatic impairment (Child-Pugh B or C) is a contraindication due to unknown effects on ezetimibe glucuronide recycling; this affects a small subset of California patients with decompensated liver disease. [1]

Ezetimibe Versus PCSK9 Inhibitors: When to Use Which in California

For California patients with very-high-risk ASCVD whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe, PCSK9 inhibitors (evolocumab 140 mg subcutaneous every 2 weeks, or alirocumab 75 to 150 mg subcutaneous every 2 or 4 weeks) represent the next escalation. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced LDL-C by 59 percent from baseline and reduced the composite MACE endpoint by 15 percent relative to placebo (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). [13]

PCSK9 inhibitors cost $500 to $700 per month list price in California, far exceeding ezetimibe's generic cash price. Most California commercial plans require step therapy documentation showing adequate trial of both high-intensity statin and ezetimibe before approving PCSK9 inhibitor PA. Starting ezetimibe first is therefore not only clinically appropriate but practically necessary for downstream PCSK9 inhibitor access.

For patients with heterozygous familial hypercholesterolemia (HeFH), the ACC/AHA guidelines suggest that LDL-C goals below 70 mg/dL in high-risk patients may require the statin-plus-ezetimibe-plus-PCSK9-inhibitor triple combination. The ODYSSEY OUTCOMES trial (N=18,924) confirmed that alirocumab added to statin therapy reduced major adverse cardiovascular events in post-ACS patients, with an absolute risk reduction of 1.7 percentage points over a median 2.8-year follow-up. [14]

What California Patients Pay Out-of-Pocket: 2026 Summary

Generic ezetimibe 10 mg costs approximately $15 per month cash-pay at California retail pharmacies in 2026. Medi-Cal covers it with PA. Commercial plans typically place it at Tier 1 to Tier 2 with $0 to $20 copays. Compounded ezetimibe from a California-licensed 503A pharmacy runs $0 to $30 per month and is legally available with a valid prescription.

The single most effective cost-reduction action for uninsured California patients is to ask for generic ezetimibe by name and apply a GoodRx coupon or use Cost Plus Drugs for mail delivery. At $15 per month, the cost barrier to a drug with demonstrated cardiovascular event reduction in IMPROVE-IT [7] is essentially eliminated for most patients.